Navigation Links
Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
Date:5/31/2008

Ritchie, USA, video

-- Ilian Cori, Bulgaria, photography

-- Diego Constantino Sossa Centurion, Argentina, essay

All contest submissions will be on display at the World Congress and will appear at events around the world in 2008.

Bayer is committed to developing innovative hemophilia A treatments and expanding scientific and clinical knowledge that improves patient care. Over the past two decades, Bayer has:

-- Invested hundreds of millions of dollars in hemophilia research,

clinical trials and post-marketing studies to ensure the safety and

efficacy of its Kogenate(R) products.

-- Supported local and international hemophilia patient groups such as the

WFH in their advocacy and patient care initiatives.

-- Supported innovative educational and training programs to improve the

diagnosis and care of people with bleeding disorders around the world.

-- Donated more than 30 million international units of product to

countries with limited access to hemophilia treatment, bringing hope

and saving lives.

About Kogenate(R) FS

Kogenate(R) FS (Antihemophilic Factor [Recombinant]) is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate(R) FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate(R) FS. Please see the full prescribing information for important risk and use information at http://www.kogenatefs.com.

About Hemophilia A

Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots
'/>"/>

SOURCE Bayer HealthCare
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
4. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
5. Thomson Healthcare Cancer Profiler Used in Study
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
8. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
9. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
10. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
11. Survey Finds U.S. Healthcare Facilities Not Doing Enough to Curb MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Md. , May 21, 2013 ... disposable drug-free consumer electronic devices, announced that CEO, ... presenting today to the FDA,s Medical Advisory Committee, ... the company,s products for over the counter sales. ... FDA developed its medical device classification schema," Whelan ...
(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue:   ... Optical Coherence Tomography (OCT) ... OBJECTIVES   BCC,s ... offer synopsis of the current and future ...
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 /PRNewswire/ ... Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ... positive Phase 2a study results of dupilumab (SAR231893/REGN668) in ... monoclonal antibody targeting the alpha subunit of the interleukin ... IL-4 and IL-13, drivers of Th2 (Type 2 helper ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7
... N.Y., Dec. 22 Cold Spring Publishing, LLC, announced ... change to Harborside Press, LLC. , In addition, Harborside Press ... over the past year requires a substantial expansion in personnel and ... the new offices of Harborside Press will be located at 37 ...
... , JACKSON, Miss., Dec. 22, 2009 University of ... VISICU e ICU® Program to enhance care of the critically ... in the region to implement the eICU Program, UMHC will serve ... UMHC is using the Philips VISICU eICU Program and ...
Cached Medicine Technology:University of Mississippi Health Care Implements Philips VISICU eICU(R) Program 2University of Mississippi Health Care Implements Philips VISICU eICU(R) Program 3
(Date:5/21/2013)... Spring is the perfect time to get ... with whole foods to weather perfect for outdoor exercise. ... the nutrition experts at Brilliant Nutrition highlight five spring ... 1. Eating Locally, With the abundance of fresh farmers' ... explore, spring is a great time to take advantage ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Standard advice ... test-drive and little else. However given industry’s less than ... to shoppers via the internet, Consumer Mattress Reports sets ... “ Choosing The Best Mattress .” , This article ... tips and suggestions that may not be readily apparent ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Patients of Dr. ... who have lost teeth due to gum disease and would ... for gum disease treatment with laser gum surgery. ... have the highest success rate out of all tooth replacement ... is a relatively new procedure cleared by the Food and ...
(Date:5/21/2013)... BOSTON (May 21, 2013) Prostaglandin analogues (PGAs), drugs ... of treatment for people with glaucoma, but their use ... with blurred vision, dryness, changes in eye color and ... that these drugs also cause upper and lower eyelid ... The findings are described in PLOS ONE . ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 HealthSmart continues ... expanding national presence has required the hiring of new ... HealthSmart is pleased to announce that Dawn Powell has ... serving as the Director of Account Management in the ... offices in Irving, Texas. With extensive client management, employee ...
Breaking Medicine News(10 mins):Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 2Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 3Health News:Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article 2Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:Glaucoma drug can cause droopy eyelids 2Health News:New Talent Joins the HealthSmart Account Management Team 2
... finds 12-month course of valganciclover wards off ... News) -- Extended antiviral treatment after a lung ... rejection, a new study from Duke University Medical ... in lung transplant recipients is cytomegalovirus (CMV), which ...
... the potentially powerful influence of political pressure on ... that use of a largely unproven mammography screening ... cost. Joshua Fenton, assistant professor in the ... with colleagues from the University of Washington and ...
... to new targets, treatments, researcher says , MONDAY, June 14 ... new regions of the human genome that may be related ... in the June issue of the Archives of ... at risk for the devastating dementia just yet, however. , ...
... around 200,000 people in Sweden have been diagnosed with ... be helped by mechanical heart pumps, reveals a thesis ... a total of 99 patients with life-threatening heart failure ... long-term circulatory support., "Two-thirds of these patients survived," says ...
... Men with this history are more prone to hit and ... -- Men who attempted suicide before age 18 are much ... a study from the Oregon Social Learning Center in Eugene. ... neighborhoods who were assessed annually from ages 10 to 32. ...
... According ... within 6 months. Amgen’s Prolia is the newest product to enter the market. Prolia ... ... to a recent analysis by SDI , a leading healthcare market insight and analytics ...
Cached Medicine News:Health News:Longer Antiviral Therapy Reduces Lung Transplant Complications 2Health News:Use of unproven mammography tool soars with Medicare coverage 2Health News:Scientists Spot More Genes Related to Alzheimer's 2Health News:Teen Boys Who Attempt Suicide More Likely to Abuse as Adults 2Health News:SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option 2
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Trident Hemispherical Acetabular Shells are a true hemispherical shape designed to achieve press-fit fixation by under-reaming the acetabulum....
For primary and revision cases...
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Medicine Products: